| Report | Options implied | Actual move | Market was |
|---|---|---|---|
| 10/23/2026 | ±3.8% | +1.9% | over-priced |
| 07/24/2026 | ±4.6% | -1.9% | over-priced |
| 04/24/2026 | ±5.0% | -1.8% | over-priced |
| 02/06/2026 | ±3.5% | -1.1% | over-priced |
| 10/23/2025 | ±4.2% | +0.9% | over-priced |
| 07/29/2025 | ±4.7% | +1.1% | over-priced |
| 04/24/2025 | ±4.0% | +6.6% | under-priced |
| 02/14/2025 | ±1.9% | +1.2% | over-priced |
| Quarter | EPS (dil.) | Revenue | Net income |
|---|---|---|---|
| Q3 FY2026 | $2.62 | $6.1B | $2.4B |
| Q2 FY2026 | $2.14 | $5.5B | $2.0B |
| Q1 FY2026 | $1.68 | $4.8B | $1.5B |
| Q4 FY2025 | — | $4.4B | $1.2B |
TXN (TXN) reports in 86 days, with the next report estimated for 01/22/2027. Across the last 8 reports, options priced an average ±4.0% earnings move while the stock actually moved 2.1% on average — the market has systematically over-priced TXN's earnings risk. Fundamentals into the print: EPS up 77.0% year-over-year, revenue up 27.7%. QuantLogix's live 5-factor engine currently reads TXN as a buy at 80/100.
Implied move is derived from at-the-money option pricing; actual moves are close-to-close on report days. Next-report dates are estimates until confirmed by the company. Educational market analysis, not investment advice. Browse all signal scorecards →